The Motley Fool··Lee SamahaGrail Stock Surges on Analyst Optimism Despite Cancer Test Setback
Grail stock jumped 11.4% as Wall Street analysts see upside in its cancer detection test despite February trial disappointment.
GRALFDA approvalcancer detection